
COVID-19 and the Impact on Clinical Trials
As COVID-19 continues to evolve, pharmaceutical, biologic, and medical device companies conducting or planning to conduct clinical trials continue to face challenges that directly impact clinical trials.
Insights into how companies are managing pandemic-related risk and how your policies may respond.
As COVID-19 continues to evolve, pharmaceutical, biologic, and medical device companies conducting or planning to conduct clinical trials continue to face challenges that directly impact clinical trials.
California’s Insurance Commissioner, Ricardo Lara approved several regulatory amendments, submitted by the Workers’ Compensation Insurance Rating Bureau (WCIRB). The new regulations are effective July 1,
As local and state governments begin to lift shelter in place orders, companies are beginning to prepare their return to work plans. Successful reentry plans
As information on COVID-19 continues to evolve, we will bring you information from trusted sources to ensure you are well-informed. Read here for updates from our OH&S Team.
UPDATE – May 15, 2020: In a press release, California Insurance Commissioner Ricardo Lara requests that the grace period to pay insurance premiums be extended until July 14, 2020, which is 60 days from the date of this notice. Review original request here.
UPDATE – May 15, 2020: In a press release, California Insurance Commissioner Ricardo Lara extended his previous order requiring insurance companies to partially return insurance premiums amid the ongoing COVID-19 pandemic. The order now includes the month of May, in addition to the already included months of March and April. Review original request here.
While the facts, circumstances, and policy language for each potential loss must be carefully reviewed in order to determine how coverage may or may not respond, outside factors such as local, state, and federal government intervention is keeping this a fluid and developing situation. The following guidelines represent current best practices, and we encourage you to follow them in a timely manner.
The Centers for Disease and Prevention (CDC) has recently posted an update for General Business employers related to COVID-19. Our Property & Casualty OH&S Team rounded up highlights to keep you informed and your employees safe.
Fed/OSHA released an enforcement memo on Friday, April 10, clarifying their guidance to compliance safety and health officers regarding positive COVID-19 cases. Learn more here.
According to the Occupational Safety and Health Administration (OSHA), most American workers will likely experience low (caution) or medium exposure risk levels at their job or place of employment. We’ve put together a downloadable response protocol for your business.
COVID-19 has created an unprecedented and constantly developing situation. The ABD Life Science Practice is available to answer any questions you may have and will continue to provide important updates affecting life science companies.
The COVID-19 public health emergency has created hardships on many businesses and has impacted their ability to make timely insurance premium payments. ABD recognizes the importance of keeping your insurance program in place, so here is a welcome development from Mike Kreidler, Washington State Insurance Commissioner.
Over the past couple of weeks, the claims team has seen the impact of the coronavirus on almost all business sectors we support. Here are considerations as you navigate claims pertaining to this situation.
Our ABD Property & Casualty team is providing updates, guidance, and more regarding COVID-19. Read more for words from Rod Sockolov and Tom Whitenight, ABD’s Property and Casualty Team’s Leadership.
Copyright 2020 © ABD Insurance & Financial Services. License #0H55918 | Privacy Policy